Drug intelligence / Profile preview

PEPRX101

Development stage: Preclinical
Lead developer: Peptris Technologies
Modality: Small Molecules

Overview

PEPRX101 is a preclinical-stage repurposed drug candidate being developed by Peptris Technologies for the treatment of inflammatory diseases. Discovered and optimized using Peptris' proprietary AI-driven drug discovery platform, PEPRX101 leverages the established clinical safety profile of an approved drug to accelerate its development timeline. The asset is currently in the preclinical stage of development, with efforts focused on validating its efficacy in in vitro and in vivo models of inflammation to support its advancement toward clinical trials.

Beyond the preview

Go deeper on PEPRX101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PEPRX101.

Explore the full profile